Kornimate/medical-research-clean huggingface dataset:
dexmedetomidine vs fentanyl in controlling labor pain

Conditions: Labor Pain

Summary: as most woman experience agonizing pain throughout vaginal labor. adjuvants were added to intrathecal bupivacaine aiming to improve the quality of analgesia. this study aimed to assess the efficacy and outcome of intrathecal dexmedetomidine and fentanyl in controlling pain during delivery.

throughout vaginal deliveries, many women suffered from pain. providing suitable analgesia is crucial (lupu et al., 2023). spinal anesthesia can provide pain management (parikh et al., 2018). various types of analgesics can be combined to get the needed duration of perioperative analgesia. dexmedetomidine has been used with effective pain management outcomes (shrestha et al., 2023). fentanyl can help pain relief in short duration procedures (show et al., 2022).

Eligibility criteria:
inclusion criteria: * women planned for spontaneous vaginal delivery. exclusion criteria: * cardiac, liver or kidney disease, allergy to local anesthetics or the studied drugs, any contraindication of regional anesthesia and intrauterine growth retardation or fetal compromise.

Keywords: dexmedetomidine fentanyl intrathecal labor pain
ease tricuspid expertise-based assessment study on clinical efficacy of contour 3d® in tricuspid valve annuloplasty

Conditions: Tricuspid Valve Insufficiency

Summary: few clinical evidence for the contour 3d tricuspid annuloplasty ring exists; therefore, in order to position this product on the market, a post-market release study was completed. the purpose of this study was to evaluate the hemodynamic performance of the contour 3d® tricuspid annuloplasty ring following tricuspid valve (tv) repair in a post-market environment.

the ease tricuspid clinical trial was a prospective, non-randomized, non-interventional, post-market release study. the purpose of this study was to evaluate the hemodynamic performance of the contour 3d® tricuspid annuloplasty ring following tricuspid valve (tv) repair in a post-market environment. therefore, the primary objective of the ease tricuspid study was to evaluate the hemodynamic performance of the contour 3d® tricuspid annuloplasty ring (contour 3d ring) in subjects with tricuspid regurgitation who had a clinical indication for tv repair in a post-market use. secondary objectives included the evaluation of the effect of tv repair with the contour 3d ring on the right ventricular function, as well as the assessment of the effect of tv repair with the contour 3d ring on the functional status in subjects undergoing tv repair in a post-market environment. subjects eligible for tv repair and compliant with the enrollment criteria were considered by the investigator for inclusion in the study. to minimize bias, enrolled subjects were followed by their own physician in accordance with the center's established practice for routine follow up. follow-up sessions were planned at the physician's discretion. to meet the intended goals, appropriate clinical data were collected at baseline (pre-surgery), during the surgical procedure, at discharge and during the follow-up period at 6 months. experienced echo-cardiologists evaluated the echos. at the time of enrollment it was not certain if the subject would receive a contour 3d ring, since the surgeon might have decided during surgery that another treatment was more beneficial to the subject. in this case, the subject was terminated from the study.

Eligibility criteria:
inclusion criteria: * willing to sign and date the patient informed consent (pic) * indicated for a concomitant surgical repair of the tv * willing to return to the hospital, where the implantation originally occurred, for a 6 month follow-up visit exclusion criteria: * patients with a degenerative tv condition * patients with primary tv regurgitation * previous tv repair or replacement * stand-alone tv repair * already participating in another investigational device or drug study, possibly leading to bias and jeopardizing the scientific appropriate assessment of the study endpoints * life expectancy of less than one year * pregnant or desire to be pregnant within 12 months of the study treatment * under 18 years or over 85 years of age * patients with active endocarditis * patients with valvular retraction with severely reduced mobility * patients with a heavily calcified tv
development of automated real-time algorithms for detection of dislocation of the carpus

Conditions: Perilunate Dislocation

Summary: perilunate dislocation of the carpus is a serious lesion of the wrist which is defined by a total loss of contact of the articular surfaces capito-lunar, scapholunate and lunate-triquetral. rare by its frequency, it represents 5 to 10% of traumatic injuries of the wrist. perilunate wrist dislocation is a rare injury that goes unnoticed in 25% of cases. even with surgical treatment, 50-100% of patients will develop radiocarpal and/or midcarpal osteoarthritis.


Eligibility criteria:
inclusion criteria : * major subjects (≥18 years old) * treated at the university hospitals of strasbourg for a carpal dislocation * presence of carpal radiographs that may indicate the presence of a lesion * subjects who have not expressed their opposition, after information, to the re-use of their data for the purposes of this research exclusion criteria : * subject having expressed his opposition to participate in the study * subject under legal protection, guardianship or curatorship

Keywords: perilunate dislocation carpus dislocation radiocarpal osteoarthritis mid-carpal osteoarthritis
using deep learning and radiomics to diagnose benign and malignant breast lesions based on ultrasound

Conditions: Breast Diseases

Summary: this retrospective study aimed to create a prediction model using deep learning and radiomics features extracted from intratumoral and peritumoral regions of breast lesions in ultrasound images, to diagnose benign and malignant breast lesions with bi-rads 4 classification. materials and methods: patients who visited in the first affiliated hospital of shandong first medical university ＆ shandong provincial qianfoshan hospital were collected. their general clinical features, information on preoperative ultrasound diagnosis, and postoperative pathologic data were reviewed.


Eligibility criteria:
inclusion criteria: * female patients with us-visible solid breast masses who underwent biopsy and/or surgical resection, and were classified as having bi-rads 4 lesions in medical us reports. exclusion criteria: * preoperative endocrine therapy, chemotherapy, or radiotherapy, preoperative invasive breast operation, insufficient image quality, and no pathological results.
a study on the treatment strategy of nvg secondary to pdr

Conditions: Neovascular Glaucoma; Proliferative Diabetic Retinopathy

Summary: with the increasing incidence of proliferative diabetic retinopathy (pdr), subsequent neovascular glaucoma (nvg) has become one of the main causes of blindness in pdr patients, and the intraocular pressure of pdr patients with nvg is often stubborn. for these patients, not only is the effect of drugs in lowering intraocular pressure poor, but the results of surgery are often unsatisfactory. because of its poor prognosis, clinical research for better strategy is of great significance in the current situation. at present, for such patients, a combination of effective control of intraocular pressure and treatment of the primary disease is often used. the purpose of this study was to investigate the clinical effects of preoperative with/without intraoperative anti-vascular endothelial growth factor (vegf) drug therapy combined with pars plana vitrectomy (ppv), pan-retinal photocoagulation (prp), and pressure-reducing valve implantation in patients with nvg secondary to pdr. furthermore, the changes of neurotrophic factors in the vitreous humor before and after anti-vegf treatment will be explored.


Eligibility criteria:
inclusion criteria: * male or female patients aged over 18 years diagnosed with type 1 or 2 diabetic mellitus (dm) confirmed by experienced endocrinologists. active pdr and nvg was clinically evident across these patients. the indications to perform surgery included vitreous hemorrhage or fibrous proliferation in the macular area, together with uncontrolled intraocular pressure. exclusion criteria: * (i) coexistent ocular disease that may interfere with visual outcome; (ii) previous history of vitrectomy or anti-vegf pharmacotherapy in either eye; (iii) a macula-involving retinal detachment for \>6 months in the study eye; (iv) severe external ocular infection; (v) usage of anticoagulant or antiplatelet therapy; (vi) preoperative or postoperative poor diabetes control \[serum hemoglobin a1c (hba1c) \>11.0%\]; (vii) uncontrolled systemic diseases, such as hypertension, cardiac diseases or presenting abnormal coagulation-associated blood diseases.
the risk stratification in patients with multiple myeloma based on fluorescence flow cytometry quantitative determination of the circulating plasma cells in the peripheral blood

Conditions: Myeloma Multiple

Summary: the main aim of this study is to evaluate the effectiveness of the clinical application of the xn-1000/20 hematology analyzer for risk stratification in patients with multiple myeloma based on the number of detected plasma cells in peripheral blood at the different stages of treatment. this clinical study is observational and does not involve drugs. 100 subjects with newly diagnosed multiple myeloma will be enrolled in this study and followed for 3 years.

the presence of circulating plasma cells in patients with multiple myeloma is considered as a marker for highly proliferative disease and associated with a worse prognosis. plasma cell counting is conventionally done by means of peripheral blood film morphology using light microscopy. however, this manual method is laborious as well as imprecise due to the low number of cells counted, and inter-observer variability. flow cytometry with monoclonal antibodies is unsuitable as a screening test. the procedure is not automated, and it is expensive and time consuming. therefore, new rapid, effective and inexepensive methods are needed for risk-stratification in patients with multiple myeloma. automated antibody-synthesizing or secreting cells counting from routine haematology systems (xn-1000/20) without sample preparation and in less than 1 minute will further reduce the workload in haematology laboratories and it can be used for counting circulating plasma cells in peripheral blood in patients with multiple myeloma.

Eligibility criteria:
inclusion criteria: * diagnosis: newly diagnosed symptomatic multiple myeloma * signed informed consent * no second tumors exclusion criteria: * monoclonal gammopathies of undefined significance * smoldering multiple myeloma * plasma cell leukemia
fish oil optimal dose determination study

Conditions: Sepsis

Summary: the primary objective of this trial is to determine the safety and efficacy of iv fish oil doses of 0.20 g/kg and 0.50 g/kg, compared to a control group, in critically ill patients with severe sepsis by examining organ function, blood safety and biochemical parameters, markers of systemic inflammation and innate immunological parameters

objectives: the overall objective is to determine the effect of iv fish oil on 28-day mortality of critically ill patients with severe sepsis. however, prior to such a large trial, we need to determine the optimal dose of iv fish oils in this population. therefore, the primary objective of this proposal (foiled) is to determine the safety and efficacy of iv fish oil doses of 0.20 g/kg and 0.50 g/kg, compared to a control group, in critically ill patients with severe sepsis by examining organ function, blood safety and biochemical parameters, markers of systemic inflammation and innate immunological parameters. study design: this is a multi-centre, open-label, phase i dose ranging clinical trial with prospective controls. setting: 2 tertiary care icus in germany (universitätsklinikum carl gustav carus, dresden and university hospital giessen and marburg, giessen). patients: mechanically ventilated adult patients (\>18 years old) admitted to icu with clinical evidence of sepsis, sepsis associated organ dysfunction, and high expression of inflammatory cytokines.

Eligibility criteria:
inclusion criteria: * adult icu patients * requiring invasive or non-invasive ventilation * clinical evidence of sepsis * presence of one or more organ failures exclusion criteria: * \>24 hours from admission to icu to time of consent * low level of inflammatory cytokine (il-6(qualitative assay \<100 pg/ml) * lack of commitment to full aggressive care (anticipated withholding or withdrawing treatments in the first week) * immunocompromised (post-organ transplantation, hiv, neutropenic \[\ 20 mgs/day for 6 months). * chronic non-invasive ventilation (except if they become mechanically ventilated) * platelet count of \< 30 gpt/l * pregnant patients. urine/blood tests for pregnancy will be done on all women of childbearing age by each site as part of standard of icu practice. * previous enrollment in this study * enrollment in other icu intervention study * allergy to fish or fish oil (shellfish allergy not an exclusion criterion) * has already received enteral or iv omega-3 fatty acids during this hospitalization and current icu admission.
phase ii safety and efficacy study of crizotinib in east asian patients with ros1 positive, alk negative advanced nsclc

Conditions: Non Small Cell Lung Cancer; ROS1 Proto Oncogene; Crizotinib

Summary: to assess treatment effectiveness and safety of oral crizotinib administered to east asian patients with advanced non-small cell lung cancer (nsclc) that is confirmed to be positive for a ros1 positive gene mutation (translocation or inversion) and confirmed negative for an alk mutation


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven diagnosis of nsclc that is locally advanced or metastatic * treatment-naïve or have received no more than 3 systemic treatment regimen(s) * positive for translocation or inversion events involving the ros1 gene * negative for translocation or inversion events involving the alk gene * patients with brain metastases are eligible if asymptomatic, or if treated, must be neurologically stable for at least 2 weeks and are not taking any contraindicated medications * any prior treatment (chemotherapy, radiation \[except for palliative\], or surgery) must have been completed at least 2 weeks prior to initiation of study medication * at least 1 measurable tumor lesion as per recist v1.1 * female or male, 18 years of age or older * ecog performance status 0 to 1 * adequate organ function * signed and dated informed consent * willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, including completion of the pro measures * agree to use effective contraception during the study period and for at least 90 days after completion of the study treatment exclusion criteria: * current treatment on another therapeutic clinical trial * prior therapy specifically directed against alk or ros1 fusion genes * spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function, carcinomatous meningitis, or leptomeningeal disease * known interstitial fibrosis or interstitial lung disease * myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack within 3 months prior to start of study treatment * ongoing cardiac dysrhythmias of nci ctcae v4.03 grade \>/=2, uncontrolled atrial fibrillation of any grade, or qtc \>470 msec * pregnant or breast feeding * use of drugs or foods that are known potent cyp3a4 inhibitors or inducers * use of other anti-cancer drugs including traditional chinese medicine on the sfda list * evidence of active malignancy within last 3 years

Keywords: non small cell lung cancer nsclc ros1 ros1 positive ros1 proto oncogene c ros tyrosine kinases ros1 positive nsclc ros1 lung cancer alk negative lung carcinoma neoplasm crizotinib xalkori previously treated or untreated north east asian
radiological and functional outcomes of internal fixation methods for ipsilateral femoral neck and shaft fractures in young adult patients

Conditions: Ipsilateral Neck and Shaft Fractures and Internal Fixation Method and Follow Up At One Year Postoperative for Radiological and Functional Outcomes

Summary: does the single construct produce more favourable radiological and functional outcomes with less complication when it is compared to dual constructs for fixation of ipsilateral femoral neck and shaft fractures in young adult patients at one year follow up?

the investigators will do follow up for internal fixation methods for ipsilateral femoral neck and shaft fractures in young adult patients at one year and observe does single construct will give favourable outcomes versus dual constructs?

Eligibility criteria:
inclusion criteria: * age of the patients from 18 to 55 years * recent fracture within one week * ipsilateral neck and shaft femur fractures according to ao classification including 31 b (all types of neck ) and 32 a,b and c ( all types of shaft femur ) exclusion criteria: * open fractures giii * patients more than 55 and less than 18 years old * patient with comorbidities: uncontrolled d.m, renal patient, neurological deficits.

Keywords: radiological and functional outcomes of internal fixation methods for ipsilateral femoral neck and shaft fractures in young adult patients
observational study on prevalence of host and viral genotypes in chronic hepatitis b and hepatitis c patients in india

Conditions: Hepatitis B; Hepatitis C

Summary: this study will define the substantial disease burden associated with viral hepatitis in india, and provide a foundation to understand the host and viral determinants of disease pathogenesis that may ultimately impact treatment decisions and outcome

the overall goal of this study is to correlate the host and viral genetics of patients infected with viral hepatitis with their clinical presentation. this study will provide the first nation-wide estimate of key host genetic polymorphisms associated with immune response, such as in the il28b gene locus which has been associated with treatment outcomes in hepatitis c. characterization of hcv and hbv viral genotypes and sub-types across different geographic regions will allow for an exploration of associations between host and viral genotypes. another objective of this study is to identify co-morbid illness and metabolic factors that are associated with chronic liver disease due to viral hepatitis. finally, this survey will explore patient awareness of their disease, risk factors for disease progression, and their treatment options

Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent * male or female, age \>= 18 * willing and able to comply with the visit procedure * prior diagnosis of chronic hcv infection or chronic hbv infection exclusion criteria: * history of difficulty with blood collection and/or poor venous access for the purposes of phlebotomy * history of bleeding disorder * blood loss requiring transfusion or \> 3 g/dl decrease in hemoglobin within 4 days of the visit * knowingly co-infected with hcv/hbv or with hiv * currently undergoing therapy for chronic hepatitis c or chronic hepatitis b * currently receiving treatment with any other investigational agent or device -- enrolled in another clinical study evaluating a treatment or procedure

Keywords: hbv, hcv, chronic, india, observational study, prevalence, genotypes, snps, viral hepatitis
therapeutic horsemanship in veterans

Conditions: Post Traumatic Stress Disorder; Traumatic Brain Injury

Summary: the project partnered with u.s. military veterans with a premier accredited therapeutic riding center for six weeks. the veterans interacted with horses by grooming and learning about them, as well as riding them for one hour per week during which they gained a variety of skills. we hoped the veterans would experience a reduction in post traumatic stress disorder (ptsd) symptoms, depression, and loneliness, while improving their social and emotional health and self-efficacy.

large numbers of post-deployed u.s. veterans diagnosed with post traumatic stress disorder (ptsd) and/or traumatic brain injury make effective interventions urgent, to reduce symptoms and increase veterans' coping. ptsd includes anxiety, flashbacks, and emotional numbing. symptoms expand health care costs for stress-related illnesses making veterans' civilian life difficult. the proposed study used a randomized experimental design with repeated measures and waitlist control group testing the efficacy of a 6-week human-horse interaction and systematic therapeutic horseback riding program in: decreasing ptsd symptoms, increasing coping self efficacy, emotion regulation, and social engagement. the riding group spent one hour weekly interacting with and riding the same horse at one of two path-accredited riding centers in mid-missouri supervised by an occupational therapist, profession association of therapeutic horsemanship (path) international-certified instructor, leader and side walkers as needed. riding was directed by a systematic lesson plan. data collection occured at baseline, 3 weeks, and 6 weeks. the control group was assessed at the same intervals and again 3 weeks and 6 weeks after joining the riding group.

Eligibility criteria:
inclusion criteria: * age 18 years or older * veterans, left active military service (not serving in reserve units.) * diagnosed with post traumatic stress disorder/traumatic brain injury or both according to icd-9 diagnostic codes. * weight less than 220 pounds. * able to walk at least 25 feet without the assistance of a person (but potentially with assistive devices). * willing to interact with and ride a horse. * have not ridden a horse in the past year. * care provider assent exclusion criteria: * age less than 18 years * veterans in active military service (including reserve units). * no diagnosis of ptsd/tbi or both according to icd-9 diagnostic codes. * weight greater than 221 pounds. * unable to walk at least 25 feet without the assistance of a person (but potentially with assistive devices.) * unwilling to interact with and ride a horse. * have been riding a horse in the past year. * care provider unwilling to provide assent
remote ischemic conditioning of the human brain in dementia patients

Conditions: Mild Cognitive Impairment; Dementia; Intermittent Claudication

Summary: the study investigates the incidence of remote ischemic conditioning in mild cognitive impairment and dementia patients

the investigators will study the potential neuroprotection of ischemia/reperfusion (i/r) of a peripheral organ or tissue against cerebral i/r injury in people with mild cognitive impairment as well as early and middle stage dementia. this crossover study will be held with individuals suffering from peripheral arteriopathy that can cause intermittent claudication after structured exercise, thus inducing extensive transient leg's ischemia.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of mild cognitive impairment * clinical diagnosis of mild dementia * clinical diagnosis of moderate dementia * peripheral arteriopathy exclusion criteria: * clinical diagnosis of severe dementia * not being able to follow the exercise program for more than two days for any reason